Key facts
- This page summarizes Leila Alland's Form 4 filing for PMV Pharmaceuticals, Inc. (PMVP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Sep 2023, 16:22.
Leila Alland - 15 Sep 2023 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- PMVP
- Reported as of
- 15 Sep 2023
- Net transaction value
- -$41,646
- SEC form
- 4
- Accepted by SEC
- 18 Sep 2023, 16:22:58 UTC
- Prior SEC filing
- 16 Jun 2023
- Next SEC filing
- 29 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Winston Kung, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Leila Alland filed Form 4 for PMV Pharmaceuticals, Inc. (PMVP) on 18 Sep 2023.
Change
- Previous filing in this sequence was filed on 16 Jun 2023.
- Current net transaction value: -$41,646.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PMVP
transaction
Common Stock
Sale
- Transaction value
- $41,646
- Shares
- -6,291
- Change %
- -12%
- Price
- $6.62
- Shares after
- 45,909
- Date
- 15 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.